Key clinical point: Combination B-cell immunomodulatory therapy with rituximab and belimumab shows considerable promise for treatment of SLE, including lupus nephritis.
Major finding: Eight of 12 patients with active lupus nephritis experienced a long-term renal response to the rituximab/belimumab combo.
Study details: SYNBIoSe-1 was a phase 2a, open-label, single-arm, 104-week, proof-of-concept study of 15 patients with severe SLE.
Disclosures: The presenter reported having no financial conflicts regarding the SYNBIoSe-1 study, which was funded by research grants from the Dutch Kidney Foundation and the Netherlands Organization for Health Research and Development.
Reproting from LUPUS 2019